{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T02:05:28Z","timestamp":1768442728424,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.clinthera.2012.11.004","type":"journal-article","created":{"date-parts":[[2012,11,27]],"date-time":"2012-11-27T13:45:46Z","timestamp":1354023946000},"page":"2333-2338","source":"Crossref","is-referenced-by-count":24,"title":["Time\u2013Action Profile of an Oral Enteric Insulin Formulation in Healthy Chinese Volunteers"],"prefix":"10.1016","volume":"34","clinical-trial-number":[{"clinical-trial-number":"chictr-trc-12001872","registry":"10.18810\/chictr"}],"author":[{"given":"Jiaqi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honglin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yerong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2012.11.004_bib1","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/sj.ijo.0802173","article-title":"When oral agents fail: practical barriers to starting insulin","volume":"26","author":"Korytkowski","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.clinthera.2012.11.004_bib2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/diacare.20.3.292","article-title":"NIDDM patients' fears and hopes about insulin therapy","volume":"20","author":"Hunt","year":"1997","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2012.11.004_bib3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/(SICI)1096-9136(199704)14:4<321::AID-DIA356>3.0.CO;2-H","article-title":"Needle phobia in type 1 diabetes mellitus","volume":"14","author":"Zambanini","year":"1997","journal-title":"Diabet Med"},{"key":"10.1016\/j.clinthera.2012.11.004_bib4","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1046\/j.1464-5491.2003.01076.x","article-title":"Alternative routes of insulin delivery","volume":"20","author":"Owens","year":"2003","journal-title":"Diabet Med"},{"key":"10.1016\/j.clinthera.2012.11.004_bib5","series-title":"Frontiers in Insulin Pharmacology","first-page":"144","article-title":"Oral insulin 1922\u20131992","author":"Berger","year":"1993"},{"key":"10.1016\/j.clinthera.2012.11.004_bib6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00063030-200519030-00003","article-title":"Oral delivery of peptide drugs: barriers and developments","volume":"19","author":"Hamman","year":"2005","journal-title":"BioDrugs"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2012.11.004_bib7","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1002\/dmrr.207","article-title":"Development of oral insulin: progress and current status","volume":"18","author":"Still","year":"2002","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.clinthera.2012.11.004_bib8","series-title":"Protein Delivery: Physical Systems","first-page":"343","article-title":"Insulin formulation and delivery","author":"Brange","year":"1997"},{"key":"10.1016\/j.clinthera.2012.11.004_bib9","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/bmj.328.7450.1215","article-title":"Inhaled insulin","volume":"328","author":"Amiel","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2012.11.004_bib10","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0022-3565(24)38943-8","article-title":"Hypoglycemic effect of insulin-transferrin conjugate in streptozotocin-induced diabetic rats","volume":"295","author":"Xia","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2012.11.004_bib11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jconrel.2004.03.008","article-title":"Mucosal insulin delivery systems based on complexation polymer hydrogels: effect of particle size on insulin enteral absorption","volume":"97","author":"Morishita","year":"2004","journal-title":"J Control Rel"},{"key":"10.1016\/j.clinthera.2012.11.004_bib12","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1023\/A:1018997101542","article-title":"Cyclodextrins as mucosal absorption promoters of insulin","volume":"11","author":"Shao","year":"1994","journal-title":"Pharm Res"},{"key":"10.1016\/j.clinthera.2012.11.004_bib13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0306-3623(91)90440-H","article-title":"Insulin and C-peptide levels following oral administration of insulin in intestinal-enzyme protected capsules","volume":"22","author":"Gwinup","year":"1991","journal-title":"Gen Pharmacol"},{"key":"10.1016\/j.clinthera.2012.11.004_bib14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2337\/diacare.27.1.239","article-title":"Concept, strategies, and feasibility of noninvasive insulin delivery","volume":"27","author":"Ceflau","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2012.11.004_bib15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1517\/17425247.5.1.45","article-title":"Nanoparticle strategies for the oral delivery of insulin","volume":"5","author":"Damg\u00e9","year":"2008","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.clinthera.2012.11.004_bib16","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/BF01062108","article-title":"Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve","volume":"6","author":"Chiou","year":"1978","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1016\/j.clinthera.2012.11.004_bib17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(01)05415-0","article-title":"Type 1 diabetes: new perspectives on disease pathogenesis and treatment","volume":"358","author":"Atkinson","year":"2001","journal-title":"Lancet"},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2012.11.004_bib18","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/sj.ijo.0802173","article-title":"When oral agents fail; practical barriers to starting insulin","volume":"26","author":"Korytkowski","year":"2002","journal-title":"Int J Obes"},{"key":"10.1016\/j.clinthera.2012.11.004_bib19","doi-asserted-by":"crossref","first-page":"666","DOI":"10.2337\/diacare.9.6.666","article-title":"Lessons from studies of insulin pharmacokinetics","volume":"9","author":"Skyler","year":"1986","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2012.11.004_bib20","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2174\/1381612013397384","article-title":"Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary insulin delivery","volume":"7","author":"Heinemann","year":"2001","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.clinthera.2012.11.004_bib21","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1089\/1520915041705929","article-title":"The physiological rationale for oral insulin administration","volume":"6","author":"Arbit","year":"2004","journal-title":"Diab Technol Ther"},{"key":"10.1016\/j.clinthera.2012.11.004_bib22","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jcem-56-6-1294","article-title":"Hepatic removal of insulin in normal man: dose response to endogenous insulin secretion","volume":"56","author":"Eaton","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2012.11.004_bib23","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1463-1326.2010.01213.x","article-title":"A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects","volume":"12","author":"Khedkar","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2012.11.004_bib24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1464-5491.1989.tb01154.x","article-title":"The action profiles of human NPH insulin preparations","volume":"6","author":"Starke","year":"1989","journal-title":"Diabet Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812006224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812006224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T21:51:22Z","timestamp":1745358682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291812006224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0149291812006224"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.11.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}